{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:49:56Z","timestamp":1791272996231,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002907","name":"Coloplast","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ajog.2020.06.032","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:20:35Z","timestamp":1592392835000},"page":"890.e1-890.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1112-9593","authenticated-orcid":false,"given":"Shannon L.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"St Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyueun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2020.06.032_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GRF.0000000000000380","article-title":"Genitourinary syndrome of menopause","volume":"61","author":"Shifren","year":"2018","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.06.032_bib2","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women\u2019s Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2147\/IJWH.S44579","article-title":"Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy","volume":"5","author":"Parish","year":"2013","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ajog.2020.06.032_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ajog.2016.07.045","article-title":"Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management","volume":"215","author":"Gandhi","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.06.032_bib5","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/GME.0b013e3182a122c2","article-title":"Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society","volume":"20","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib6","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/GME.0000000000001220","article-title":"17\u03b2-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis","volume":"25","author":"Rioux","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib7","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/GME.0000000000001221","article-title":"A\u00a0systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause","volume":"26","author":"Biehl","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/gme.0b013e3181a48c4e","article-title":"Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally","volume":"16","author":"Bachmann","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/AOG.0000000000000526","article-title":"Vaginal estrogen for genitourinary syndrome of menopause: a systematic review","volume":"124","author":"Rahn","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.06.032_bib11","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/GME.0000000000000465","article-title":"One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophy","volume":"22","author":"Portman","year":"2015","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/GME.0000000000000729","article-title":"Compliance to vaginal treatment\u2014tablets versus cream: a retrospective 9 years study","volume":"24","author":"Weissmann-Brenner","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJWH.S41897","article-title":"Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy","volume":"5","author":"Minkin","year":"2013","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ajog.2020.06.032_bib14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jwh.2007.0407","article-title":"A\u00a0retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice","volume":"17","author":"Shulman","year":"2008","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.ajog.2020.06.032_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/SPV.0b013e3181ab4804","article-title":"Local effects of vaginally administered estrogen therapy: a review","volume":"15","author":"Krause","year":"2009","journal-title":"J\u00a0Pelvic Med Surg"},{"key":"10.1016\/j.ajog.2020.06.032_bib16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/cer-2019-0091","article-title":"Ospemifene versus local estrogen: adherence and costs in postmenopausal dyspareunia","volume":"8","author":"Faught","year":"2019","journal-title":"J\u00a0Comp Eff Res"},{"key":"10.1016\/j.ajog.2020.06.032_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/13697137.2013.834493","article-title":"Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy","volume":"17","author":"Goldstein","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/13697137.2014.954996","article-title":"Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial","volume":"18","author":"Constantine","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.maturitas.2014.02.015","article-title":"Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomized, placebo-controlled, phase III trial","volume":"78","author":"Portman","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2020.06.032_bib21","first-page":"1939","article-title":"Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause","volume":"9","author":"Wurz","year":"2014","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ajog.2020.06.032_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/13697137.2014.975199","article-title":"The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy","volume":"18","author":"Nappi","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib23","first-page":"487","article-title":"The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis","volume":"11","author":"Cui","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2020.06.032_bib24","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/074880681102800309","article-title":"Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation","volume":"28","author":"Gaspar","year":"2011","journal-title":"Am J Cosmet Surg"},{"key":"10.1016\/j.ajog.2020.06.032_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/lsm.22637","article-title":"Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies","volume":"49","author":"Tadir","year":"2017","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.ajog.2020.06.032_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/lsm.23126","article-title":"The effect of fractional CO2 laser treatment on the symptoms of pelvic floor dysfunctions: Pelvic Floor Distress Inventory-20 Questionnaire","volume":"51","author":"Sipos","year":"2019","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.ajog.2020.06.032_bib27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00192-017-3437-x","article-title":"A\u00a0systematic review on vaginal laser therapy for treating stress urinary incontinence: do we have enough evidence?","volume":"28","author":"Pergialiotis","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ajog.2020.06.032_bib28","first-page":"215","article-title":"Effect of single-treatment, surface-cooled radiofrequency therapy on vaginal laxity and female sexual function: the VIVEVE I randomized controlled trial","volume":"14","author":"Krychman","year":"2017","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.ajog.2020.06.032_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3109\/13697137.2014.975197","article-title":"Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy","volume":"18","author":"Salvatore","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib30","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/GME.0000000000001121","article-title":"Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from the North American Menopause Society and the International Society for the Study of Women\u2019s Sexual Health","volume":"25","author":"Faubion","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00192-018-3830-0","article-title":"IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity","volume":"30","author":"Shobeiri","year":"2019","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ajog.2020.06.032_bib32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/GCO.0000000000000399","article-title":"Lasers for pelvic floor dysfunctions: is there evidence?","volume":"29","author":"Lang","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ajog.2020.06.032_bib35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.maturitas.2017.06.029","article-title":"Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis","volume":"103","author":"Pitsouni","year":"2017","journal-title":"Maturitas"},{"key":"10.1016\/j.ajog.2020.06.032_bib36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/13697137.2017.1319815","article-title":"Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women","volume":"20","author":"Siliquini","year":"2017","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/13697137.2014.899347","article-title":"A\u00a012-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study","volume":"17","author":"Salvatore","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.ajog.2020.06.032_bib38","first-page":"150","article-title":"Microablative fractional CO2 laser improves dyspareunia related to vulvovaginal atrophy: a pilot study","volume":"6","author":"Salvatore","year":"2014","journal-title":"J\u00a0Endometr"},{"key":"10.1016\/j.ajog.2020.06.032_bib39","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/GME.0000000000000839","article-title":"Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes","volume":"24","author":"Sokol","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/GME.0000000000000700","article-title":"An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy","volume":"23","author":"Sokol","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/asj\/sjy087","article-title":"Treatment to external labia and vaginal canal with CO2 laser for symptoms of vulvovaginal atrophy in postmenopausal women","volume":"39","author":"Samuels","year":"2019","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.ajog.2020.06.032_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/GME.0000000000000955","article-title":"Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women","volume":"25","author":"Cruz","year":"2018","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/GME.0000000000001416","article-title":"A\u00a0randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET trial","volume":"27","author":"Paraiso","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.ajog.2020.06.032_bib44","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.urology.2017.11.026","article-title":"Percutaneous tibial nerve stimulation in the office setting: real-world experience of over 100 patients","volume":"113","author":"Sirls","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.ajog.2020.06.032_bib45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/nau.24254","article-title":"Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients","volume":"39","author":"Te Dorsthorst","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ajog.2020.06.032_bib46","first-page":"791","article-title":"Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ajog.2020.06.032_bib47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/jwh.2014.5177","article-title":"The association between vulvovaginal atrophy symptoms and quality of life among postmenopausal women in the United States and Western Europe","volume":"24","author":"DiBonaventura","year":"2015","journal-title":"J\u00a0Womens Health (Larchmt)"},{"key":"10.1016\/j.ajog.2020.06.032_bib48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jval.2015.11.002","article-title":"Examining the value of menopausal symptom relief among US women","volume":"19","author":"Craig","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.ajog.2020.06.032_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00019053-199915040-00004","article-title":"Utility scores for chronic conditions in a community-dwelling population","volume":"15","author":"Mittmann","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ajog.2020.06.032_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1586\/14737167.2015.965153","article-title":"Utility values for pre-menopausal women suffering from symptomatic uterine fibroids","volume":"15","author":"Hux","year":"2015","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.ajog.2020.06.032_bib51","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jval.2010.11.017","article-title":"Utility scores and treatment preferences for clinical early-stage cervical cancer","volume":"14","author":"Jewell","year":"2011","journal-title":"Value Health"},{"issue":"11 Pt C","key":"10.1016\/j.ajog.2020.06.032_bib52","first-page":"E830","article-title":"Systematic review of the impact of urinary tract infections on health-related quality of life","volume":"110","author":"Bermingham","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ajog.2020.06.032_bib55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/lsm.22569","article-title":"Efficacy of erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause","volume":"49","author":"Gaspar","year":"2017","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.ajog.2020.06.032_bib56","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/GME.0000000000001293","article-title":"Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy","volume":"26","author":"Gordon","year":"2019","journal-title":"Menopause"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820306402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937820306402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:31:05Z","timestamp":1757590265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937820306402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0002937820306402"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2020.06.032","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2020.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}